

Powering Regenerative Medicine

Propulsons la médecine régénératrice

# Stem Cell Network – Doctoral Research Awards in Social, Ethical, and Economic Implications for Regenerative Medicine

# **Table of Contents**

4.	General Information	3
	A.1 Objective	3
	A.2 Application Submission Deadline	3
	A.3 Incomplete/Unacceptable Applications	3
	A.4 Competition Results	3
	A.5 Non-Employee Status	4
	A.6 Communicating Research to the Public and Donors	4
	A.7 Ethical Requirements	4
	A.8 Sex- and Gender-Based Analysis Plus (SGBA+) & Equity, Diversity and	
	Inclusion (EDI)	
	A.9 Patent Rights	5
	A.10 Open Science and Open Access to Research Outputs Policy	5
	A.11 Research Integrity Policy	6
	A.12 Acknowledging Publications	6
B	. Specific Program Information	7
	B.1 Eligibility	7
	B.2 Tenure	7
	B.3 Award Amount	8
	B.4 Disclosure of Other Awards	8
	B.5 Multiple SCN Personnel Awards	8



Powering Regenerative Medicine Propulsons la médecine régénératrice

B.6 Transfer of Award	8
B.7 Award Termination	9
B.8 Eligible Research Areas	9
B.9 How to Apply	9
B.10 Application Attachments	10
B.11 Letters of Support	10
B.12 Evaluation Criteria	11
B.13 Selection Committee	11
B.14 Notification of Results and Award Commencement	11
B.15 Reporting: Financial, Progress and Final Reports	11
B.16 Contact Information	11
B.17 Stem Cell Network	12



Powering Regenerative Medicine

Propulsons la médecine régénératrice

### A. General Information

Stem Cell Network – Doctoral Research Awards in Social, Ethical, and Economic Implications for Regenerative Medicine		
Competition Launch Date	June 17, 2024	
Application Deadline	September 10, 2024, 17:00 ET	
Award Notification Date	October 4, 2024	
Award Start Date	January 1, 2025 (Award must be started no later than	
	March 1, 2024)	
Value	Up to two awards each valued at \$25,000	
Contact	training@stemcellnetwork.ca	

### A.1 Objective

Through the Stem Cell Network Doctoral Research Awards in Social, Ethical, and Economic Implications for Regenerative Medicine, SCN is committing up to two awards valued at \$25,000 each in order to cultivate and train high calibre scholars equipped to navigate the complex social, ethical, and economic considerations associated with regenerative medicine, and who can contribute to the responsible development and implementation of regenerative therapies, ensuring that the benefits are equitably and ethically realized across Canada's diverse population.

## A.2 Application Submission Deadline

It is the applicant's responsibility to ensure that a completed application is submitted via ProposalCentral no later than September 10, 2024, 17:00 ET. Any applications attempted or submitted after the deadline will NOT be accepted. There will be no appeal process for late submissions.

## A.3 Incomplete/Unacceptable Applications

All submissions are considered final. No alterations or changes will be accepted. Any incomplete applications, as noted in this guideline document, will not be admissible to the competition.

## **A.4 Competition Results**

Official notification of the competition outcomes will be sent to all applicants on October 4, 2024.



Powering Regenerative Medicine

Propulsons la médecine régénératrice

### **A.5 Non-Employee Status**

The granting of an award is deemed to establish neither an employer-employee relationship nor a partnership between the SCN and the recipients.

## A.6 Communicating Research to the Public and Donors

Successful applicants should be aware that the title of their research program and the lay summary could be placed into the public domain or included in SCN publications without notification. Applicants are cautioned not to disclose information that could endanger a proprietary position in these sections.

SCN has a responsibility to report the types and impact of the investments it makes to the Government of Canada. As successful applicants are well-positioned to explain their research, they may be asked by SCN to communicate the importance of research to the public, via interviews, outreach or other knowledge mobilization activities.

### **A.7 Ethical Requirements**

By signing and submitting applications to this competition, applicants undertake the responsibility to ensure any experimentation will be acceptable to the institution on ethical grounds and comply with the following guidelines and host institution research policies, as applicable:

- Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans
- Good Clinical Practice (GCP)
- Good Laboratory Practice (GLP)
- In the case of laboratory animal experimentation, the guiding principles and standards that have been enunciated by the <u>Canadian Council on Animal Care</u>
- Guidelines and standards for biological and chemical hazards as outlined in the Public Health Agency/Canadian Food Inspection Agency's Canadian Biosafety Standards and Guidelines.
- Any research involving human pluripotent stem cells must adhere to the CIHR-ICRH Guidelines for Human Pluripotent Stem Cell Research. The institution must notify SCN as to the results of the review by the CIHR Stem Cell Oversight Committee.
- TCPS2 (2022) Chapter 9: Research Involving the First Nations, Inuit, and Métis Peoples of Canada



Powering Regenerative Medicine

Propulsons la médecine régénératrice

# A.8 Sex- and Gender-Based Analysis Plus (SGBA+) & Equity, Diversity and Inclusion (EDI)

SCN is committed to advancing SGBA+ and EDI towards enhancing the specificity, representativeness, rigour and transparency of research and sustaining positive change in the regenerative medicine ecosystem. The applicants are therefore encouraged to become familiar with the principles of SGBA+ and EDI, with the goal of integrating such principles, if applicable, into future research practice and design.

- Government of Canada Best Practices in Equity, Diversity and Inclusion (EDI)
- Guide on Equity, Diversity and Inclusion Terminology
- CIHR Research Training Module: Sex and Gender Considerations
- Women's College Hospital Sex-Specific Analyses and Reporting in Clinical Trials
- TCPS2 (2022) Chapter 9: Research Involving the First Nations, Inuit, and Métis Peoples of Canada

## **A.9 Patent Rights**

SCN makes no intellectual property (IP) claims on the outputs of the funded research, and acknowledge ownership lies with the institution receiving the funds, and the institution funded is free to divest it on its own terms. However, institutions of funded recipients are expected to have appropriate policies in place to protect the IP of the outputs that arise from the funded research.

## A.10 Open Science and Open Access to Research Outputs Policy

All award recipients are required to make their research outputs and findings publicly available on open access as soon as possible but no later than 12 months after project completion or final publication. Only under exceptional circumstances, such as ongoing review of a final manuscript, will delays in data release beyond 12 months from completion of the project be acceptable. To meet this requirement, applicants should become familiar with the guiding principles, as applicable, that enable sharing data, information, tools and resources, and that respect Indigenous data governance and sovereignty.

Open Science is the practice of making scientific inputs, outputs and processes freely available to all with minimal restrictions. Open Science is enabled by



Powering Regenerative Medicine

Propulsons la médecine régénératrice

people, technology, and infrastructure. It is practiced in full respect of privacy, security, ethical considerations, and appropriate intellectual property protection. To learn more about Open Science, applicants are encouraged to review the Federal Government's Roadmap for Open Science.

- FAIR: Findable, Accessible, Interoperable, and Reusable are guiding principles to inform data management and stewardship of digital assets.
- CARE (Collective benefit, Authority to control, Responsibility and Ethics) are guiding principles for Indigenous Data Governance.
- First Nations Principles of OCAP® (Ownership, Control, Access and Possession) guide how First Nations' data should be collected, protected, used and shared.
- <u>ClinicalTrials.gov</u> is a database of privately and publicly-funded clinical trials around the world.
- PROSPERO is an international prospective register of protocols.

Research outputs may include peer-reviewed journal publications, research data, and the results of clinical trials that will not be published in peer-reviewed journals. Research findings may be shared in ways that are culturally relevant and in formats that are functional, useful and practical to distinct needs of Indigenous (First Nations, Inuit and Métis) communities. Indigenous Peoples share common histories and concepts; however, each community has specific methods for knowledge synthesis, translation, and exchange. For Indigenous knowledge mobilization to be successful, meaningful and <u>culturally safe</u>, engagement with Indigenous communities is encouraged as Indigenous communities are best positioned to guide researchers towards the co-development knowledge mobilization practices that work best for their communities.

## A.11 Research Integrity Policy

SCN conforms to the Tri-Agency Policy Framework for the Responsible Conduct of Research and expect that researchers and institutions to adhere to this policy.

## **A.12 Acknowledging Publications**

SCN must be notified in advance of the publication date of any major publications (e.g. articles in peer-reviewed journals, media articles) arising from the funded research by email at: trainingSCN@stemcellnetwork.ca. Recipients must acknowledge the support of SCN in all scientific communications and press releases related to their award with the following wording:



Powering Regenerative Medicine Propulsons la médecine régénératrice

"(Name of award recipient) is supported by a Stem Cell Network Doctoral Research Award in Social, Ethical, and Economic Implications for Regenerative Medicine."

# **B. Specific Program Information**

## **B.1 Eligibility**

#### **Applicant**

There are no citizenship requirements for this award. To assure continued excellence and diversity among applicants and awardees, SCN welcomes applications from all qualified individuals and encourage applications from persons with disabilities or members of minority groups underrepresented in the sciences.

At the time of submission, applicants must either (a) be enrolled in a full-time Doctoral program at an eligible Canadian institution at the start date of the award; (b) have applied for full-time admission to a Doctoral program at an eligible Canadian institution with a start date no later than December 1, 2024; or (c) be intending to reclassify from a Master's to a Doctoral program at an eligible Canadian institution with a start date no later than December 1, 2024.

#### Location

Individuals must take up their award with a Principal Investigator at a Canadian institution that meets the <u>eligibility criteria</u> for Tri-Agency funding.

#### **B.2 Tenure**

- Each award is for \$25,000 per year, for one year.
- The recipient or supervisor will notify SCN of any causes (parental leave, medical leave, personal leave, vacation time, etc.) necessitating absence from work exceeding 30 successive days. Continuation of the award will be evaluated on a case-by-case basis by SCN. Relevant institutional policies will also apply.
- The term of the award will include reasonable holiday time according to the arrangement with the recipient's supervisor and institution.
- Recipients may engage in and receive remuneration for departmental activities (e.g., teaching) that contribute to their development as researchers. It is expected



Powering Regenerative Medicine

Propulsons la médecine régénératrice

that these activities would not unreasonably impinge upon the time dedicated to the proposed research project.

#### **B.3 Award Amount**

Each award is for \$25,000, of which 100% will go towards stipend costs.

- This stipend may be used ONLY for salary support for the recipient. No part of this stipend is to be used to support other direct or indirect costs associated with any research programs or operating grants.
- SCN will also provide the Awardees with a registration fee and travel support to attend SCN's annual scientific meeting, the Till & McCulloch Meetings (TMM), at least once during the award term. This is an additional, non-transferrable, value of up to \$1500.00. SCN will coordinate this support directly with the Awardees.
- The Awardees will be eligible to participate in the TMM abstract and poster competitions. The Awardees will also be eligible to apply for other training opportunities offered by SCN during the duration of the Award, including technical skills, industry prep, clinical translation and EDI training.
- SCN will not provide a cost-of-living supplement for the Awardee during the duration of their award, nor expenses related to relocation.
- Please contact SCN with specific inquiries about allowable costs.

#### **B.4 Disclosure of Other Awards**

In the event that an Awardee secures another stipend award (e.g., a CIHR Doctoral award), SCN a must be immediately notified by the supervising principal investigator ("PI") or Awardee. SCN will then decide on a case-by-case basis how to proceed.

## **B.5 Multiple SCN Personnel Awards**

Applicants may submit applications to multiple SCN Personnel Awards, but they may not hold multiple Personnel Awards from SCN at one time.

#### **B.6 Transfer of Award**

Personnel Awards may not be assigned or transferred to another individual under any circumstances. Recipients of Personnel Awards are not permitted to change supervisors, programs or institutions while receiving the award. If an Awardee drops out of the



Powering Regenerative Medicine

Propulsons la médecine régénératrice

program or moves to a new institution for any reason, they must notify SCN immediately, who will then decide whether the remaining funds are returned to SCN.

#### **B.7 Award Termination**

When work under an award is complete, or if for any reason the work cannot be continued, the award will be closed. Any remaining funds will be frozen and cannot be reallocated to other uses without prior SCN permission. The institution will prepare a final Financial Report and SCN will then decide whether any remaining funds are returned to SCN.

### **B.8 Eligible Research Areas**

Eligible projects research projects must be focused on the social, ethical, and/or economic implications for regenerative medicine.

Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and use of therapeutic stem cells, tissue engineering, and the production of artificial organs. Research applications that are focused on cancer must be regenerative in nature and/or use stem cells for addressing the proposed problem.

## **B.9** How to Apply

Applicants must submit a full application to Stem Cell Network via SCN's ProposalCentral application portal by the application deadline of September 10, 2024 at 17:00 ET. An application will consist of:

- Completed application form in ProposalCentral, which will include completion of a written section:
  - o Applicant expertise
  - o Research contributions and impacts
  - o Training, mentorship, and career development plan
  - o Research project title
  - o Research proposal and justification
  - Research project lay summary
- Canadian Common CV, in CIHR academic format



Powering Regenerative Medicine

Propulsons la médecine régénératrice

Up to three (3) letters of support (minimum two, maximum three) must be submitted that assess the applicant's scientific abilities and contributions, as well as the potential of the applicant.

Applicants may apply in English or French. For technical assistance with the ProposalCentral portal, contact Customer Support at 800 875 2562 (Toll-free U.S. and Canada), +1 703 964 5840 (Direct Dial International) or by e-mail at pcsupport@altum.com.

### **B.10 Application Attachments**

Applicants must complete and submit all attachments listed below in the Upload CV and Research Proposal" section of the application form.

- Canadian Common CV, in CIHR Academic Format
- Research proposal: Please upload a single PDF document of your research proposal and references in section 7. A maximum of one page is allocated for the description of your research proposal. Applicants should detail the rationale, objective(s), methodological approach, timeline and significance/impact of their proposed research. No tables or figures are allowed. Please use 12-point Calibri or Times New Roman font, single spaced format. There is no page limit for references that are directly relevant to the project proposal; please append the references at the end of the 1-page research proposal PDF file.

## **B.11 Letters of Support**

Up to three letters of support (minimum two, maximum three) must be submitted that assess the applicant's scientific abilities and contributions, as well as the potential of the applicant. Please note that the letters of support are confidential and will not be released to the applicant. The letters of support must be submitted directly through ProposalCentral by the referee. Enter the email address of the referee below and an automated email will be sent requesting they submit a letter of support for your application. The letter(s) of support should come from the individual(s) under whom the applicant has trained, who are familiar with the candidate's characteristics and abilities and/or who have had a good opportunity to assess their potential for research.



Powering Regenerative Medicine

Propulsons la médecine régénératrice

### **B.12 Evaluation Criteria**

The application components, noted below, will be reviewed by the Selection Committee, and an overall score for each applicant will be calculated. The relative weight of each component is detailed below.

- The quality of the research proposal (weighting 25%)
- The candidate's expertise and CV (weighting: 25%)
- The candidate's contributions and research impacts (weighting: 25%)
- The candidate's career development plan (weighting: 10%)
- The letters of support: description of the candidate's abilities and research potential (weighting: 15%)

#### **B.13 Selection Committee**

Peer review of the applications will be performed by a joint committee composed of members from SCN's Training and Education Committee (TEC). All members must agree to respect the privacy, confidentiality and conflict of interest rules of SCN.

#### **B.14 Notification of Results and Award Commencement**

All applicants will be notified of the results on October 4, 2024. The award is scheduled to start between January 1, 2025, and no later than March 1, 2025.

## **B.15 Reporting: Financial, Progress and Final Reports**

The recipient's institution is required to submit (a) an annual consolidated Financial Report for the reporting period for the recipient, (b) an annual Progress Report for the recipient; and c) a final report for the recipient. More information about these requirements will be provided in the letter of offer.

In addition, recipients will be sent links to the report templates within the first year of award funding.

#### **B.16 Contact Information**

For any questions or concerns, the preferred form of communication is email.

Email: at trainingSCN@stemcellnetwork.ca



Powering Regenerative Medicine

Propulsons la médecine régénératrice

Website: https://www.stemcellnetwork.ca

Please note these email accounts are only monitored from 9am-5pm ET, Monday to Friday.

### **B.17 Stem Cell Network**

#### Stem Cell Network

The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN's goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 6,400 highly qualified personnel have been trained. In 2021, the Government of Canada demonstrated its continuing trust and support in SCN with an investment of \$45 million for the 2022-2025 period.